Skip to content
Clinical Trials – home
Therapeutic area

Nervous system disorders – page 18

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Study of Flortaucipir (18F) PET Imaging in Healthy Elderly Twins to Investigate Early Signs of Alzheimer's Disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years · Healthy volunteers
  • Substances:Flortaucipir (18F)
  • Sponsor:Amsterdam UMC Stichting

Study on Improving Social Interaction in Children with Autism Using Oxytocin Nasal Spray and Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · Healthy volunteers
  • Substances:Oxytocin
  • Sponsor:UZ Leuven

A study using [18F]RO6958948 PET imaging to examine brain tau protein deposits in people at risk of Alzheimer's Disease

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:2-(6-[18F]Fluoro-Pyridin-3-Yl)-9H-Dipyrido[2,3-B:3',4'-D]Pyrrole
  • Sponsor:Barcelonabeta Brain Research Center

Study on Dopaminergic Pathway Disruption in Comatose Patients with Traumatic Brain Injury Using [18F]LBT-999

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:Inserm

Study on Early vs. Late Restart of Anticoagulation with Edoxaban, Apixaban, and Warfarin for Patients with Chronic Subdural Hematoma and Atrial Fibrillation

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:HUS-Yhtymae

Study on Long-Term Safety and Efficacy of VX-670 for Adults with Myotonic Dystrophy Type I

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:VX-670
  • Sponsor:Vertex Pharmaceuticals Inc.

Comparison of TAK-881 and HyQvia for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Takeda Development Center Americas Inc.

Study on ITI-1284 for Treating Agitation in Alzheimer's Patients

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:ITI-1284
  • Sponsor:Intra-Cellular Therapies Inc.

Study on the Effectiveness of Lidocaine Hydrochloride and Sodium Chloride for Treating Headaches in Patients with Spontaneous Brain Bleeding

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau

Migraine

Recruiting

Study on the Safety and Effectiveness of Atogepant for Preventing Chronic Migraine in Children Aged 12 to 17

Investigational
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Safety and Effectiveness of NEU-411 for Patients with Early Parkinson's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Neuron23 Inc.

Study of RLY-2608 for Adults and Children with PIK3CA-Related Overgrowth and Malformations

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:RLY-2608
  • Sponsor:Relay Therapeutics Inc.

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.